Related Experiment Video
Updated: Jan 13, 2026
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
Elemene Augments the Effects of Anti-PD-1 Immunotherapy on Hepatocellular Carcinoma by Regulating the
Menglan Wang1, Mengqing Sun1, Heng Dong1
1Zhejiang Provincial Key Laboratory of Anti-Cancer Chinese Medicines and Natural Medicines, School of Pharmacy, Hangzhou Normal University, Department of Hepatology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou, 311121, China.
Abstract:
Immune checkpoint inhibitors, particularly PD-1 inhibitors, constitute the cornerstone of first-line treatment for hepatocellular carcinoma (HCC). However, suboptimal overall response rates persist alongside dual challenges: immune-related toxicities and immunosuppressive tumor microenvironment. Combination therapies represent a pivotal strategy to overcome these limitations. In recent years, traditional Chinese medicine has gained significant attention. Elemene, a small-molecule compound derived from Curcuma wenyujin, has garnered attention for its immunomodulatory potential and demonstrates clinical efficacy in combination therapies. Nevertheless, its synergistic mechanisms with immunotherapy remain incompletely characterized. This study demonstrates for the first time that elemene modulates the miR-130a-5p/SPP/MHC-I axis, resulting in an enhanced diversity and abundance of antigen/MHC-I complexes on the surface of HCC cells. This mechanism promotes the recognition and elimination of HCC cells by cytotoxic T lymphocytes, thereby augmenting the antitumor immune efficacy of PD-1. Moreover, the functional significance of the miR-130a-5p/SPP/MHC-I axis in modulating the tumor immune microenvironment is systematically validated through in vitro and in vivo HCC models, as well as in clinical patient specimens. These findings underscore the potential of combining elemene with anti-PD-1 therapy as a safe and effective treatment strategy for HCC, offering significant translational promise for improving patient outcomes.
Insights
Elemene enhances PD-1 immunotherapy for hepatocellular carcinoma (HCC) by modulating the miR-130a-5p/SPP/MHC-I pathway. This boosts T-cell recognition and elimination of cancer cells, improving treatment efficacy.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- Hepatocellular carcinoma (HCC) treatment relies on PD-1 inhibitors, but response rates are limited by toxicities and a suppressive tumor microenvironment.
- Combination therapies are crucial for overcoming these challenges, with Traditional Chinese Medicine compounds like Elemene showing promise.
- The precise synergistic mechanisms of Elemene with immunotherapy, particularly its impact on the tumor immune microenvironment, require further elucidation.
Purpose of the Study:
- To investigate the novel immunomodulatory mechanisms of Elemene in combination with PD-1 inhibitors for HCC.
- To elucidate the role of the miR-130a-5p/SPP/MHC-I axis in mediating Elemene's synergistic effects.
- To validate the therapeutic potential of this combination strategy in preclinical and clinical settings.
Main Methods:
- In vitro and in vivo HCC models were utilized to assess the effects of Elemene and anti-PD-1 therapy.
- The study analyzed the modulation of the miR-130a-5p/SPP/MHC-I axis and its impact on antigen presentation.
- Analysis included assessing T-cell recognition, tumor microenvironment changes, and clinical patient specimens.
Main Results:
- Elemene was found to modulate the miR-130a-5p/SPP/MHC-I axis in HCC cells.
- This modulation led to increased diversity and abundance of antigen/MHC-I complexes on HCC cell surfaces.
- The combination therapy enhanced cytotoxic T lymphocyte-mediated recognition and elimination of HCC cells, augmenting anti-PD-1 efficacy.
Conclusions:
- Elemene enhances anti-PD-1 therapy efficacy in HCC by upregulating the miR-130a-5p/SPP/MHC-I pathway, promoting anti-tumor immunity.
- This mechanism involves improved antigen presentation and T-cell-mediated tumor cell killing.
- Combining Elemene with anti-PD-1 therapy presents a promising and safe treatment strategy for HCC with significant translational potential.
More Related Videos
Related Concept Videos
02:38Mitogens and the Cell Cycle
01:27Tumor Immunotherapy